Latest Ratios: P/E Ratio -52.5x · EV/EBITDA N/A · ROE -14.2%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $651M | $484M | $253M | $25M | $151M | $200M | $335M | $879M | — | — | — |
| Enterprise Value | $589M | $422M | $207M | $17M | $143M | $180M | $319M | $866M | — | — | — |
| P/E Ratio → | -52.50 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.22 | 3.51 | 4.59 | 4.41 | 14.94 | 10.57 | 21.37 | 69.59 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.2% | -14.2% | -51.4% | -107.2% | -72.4% | -52.6% | -44.5% | -43.2% | -39.0% | -265.9% | -42.5% |
| ROA | -13.6% | -13.6% | -46.1% | -81.7% | -62.3% | -48.7% | -41.7% | -40.9% | -37.4% | -258.1% | -41.4% |
| ROIC | -29.4% | -29.4% | -321.4% | -5671.9% | -2878.6% | — | — | — | -769.7% | -1784.1% | -118.7% |
| ROCE | -17.3% | -17.3% | -53.3% | -112.6% | -72.6% | -52.7% | -46.0% | -44.2% | -41.2% | -266.7% | -42.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | 0.00 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.45 | -0.83 | -1.30 | -0.81 | -1.07 | -1.07 | -1.05 | -1.00 | -0.93 | -0.73 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -32.27 | -343.07 | -163.83 |
Net cash position: cash ($62M) exceeds total debt ($154920)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 51.35 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.32 | 29.28 | 32.48 |
| Quick Ratio | 51.35 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.32 | 29.28 | 32.48 |
| Cash Ratio | 51.33 | 51.33 | 11.46 | 4.13 | 4.19 | 12.85 | 14.22 | 18.25 | 17.25 | 28.80 | 32.13 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 5.4% | 7.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 5.4% | 7.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $11M | $15M | $13M | $12M | $11M | $11M | $10M | $10M | $10M |
Clinical trial binary outcomes
According to recent market data, Monopar trades at a price-to-book ratio of 4.71, which appears to reflect investor anticipation of clinical trial outcomes rather than current fundamental performance, as the company lacks revenue and maintains a negative trailing twelve-month price-to-earnings multiple of -47.39.
The current valuation multiple is heavily influenced by the company's cash-rich balance sheet rather than operational earnings, which are non-existent. Investors should monitor whether this premium persists if clinical milestones for Validive or MNPR-101 are delayed, as the market may be pricing in a high probability of success that is not yet supported by clinical data.
Based on reported financial statements, Monopar's return on invested capital has remained consistently negative, fluctuating between -4.9% and -22.9% over the last five quarters, which underscores the firm's status as a research-intensive entity that is currently consuming rather than compounding capital.
The negative ROIC trend is a structural reality for a pre-revenue biotech firm where all capital is deployed into R&D with no immediate return. This suggests that traditional return-on-capital metrics are less useful for assessing management performance than the efficiency of clinical trial execution and the preservation of the cash runway.
As reported in recent filings, Monopar maintains a current ratio of 56.04 as of 2026Q1, which indicates an exceptionally strong liquidity position that provides a significant buffer against the company's ongoing operational burn and potential volatility in clinical trial expenses.
This high liquidity ratio is primarily a function of the company's cash-heavy balance sheet and lack of current liabilities, suggesting that the firm is well-positioned to fund its current pipeline without immediate reliance on dilutive equity financing. However, this liquidity should be viewed as a finite resource that will inevitably deplete as clinical trials progress toward later stages.
As indicated by the company's financial history, the use of net margin or P/E ratios to evaluate Monopar is fundamentally flawed, as these metrics obscure the reality that the firm is a clinical-stage research entity with no commercial revenue or scalable operating model.
Investors should instead focus on the cash burn rate and the clinical trial timeline, as these are the true drivers of value for a pre-revenue biotech firm. Applying traditional profitability ratios to Monopar risks misinterpreting the company's R&D-driven losses as operational failure, when they are in fact the necessary cost of developing the company's pipeline.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MNPR stock.
Monopar Therapeutics Inc.'s current P/E ratio is -52.5x. This places it at the 50th percentile of its historical range.
Monopar Therapeutics Inc.'s return on equity (ROE) is -14.2%. The historical average is -68.9%.
Based on historical data, Monopar Therapeutics Inc. is trading at a P/E of -52.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.